Why has the Medibank (ASX:MPL) share price lost 11% since early January?

The private health insurer's stock is taking a hit this year. What's going on?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The Medibank share price has slipped 11% since the start of the year 
  • The company's shares fell 0.33% today 
  • A broker downgrade and elective surgery bans may have impacted the company's share price over recent months

The Medibank Private Ltd (ASX: MPL) share price has had a sluggish start to the year.

Medibank shares have fallen 11% since 4 January, the first trading day of the year. In today's trade, the share fell 0.33% to $3.05.

Let's take a look at what has been impacting the Medibank share price.

A sad looking scientist sitting and upset about a share price fall.

Image source: Getty Images

What's going on with Medibank?

The private health insurance giant's shares have had a tough start to the year after gaining 11% in 2021.

Medibank was hit with a downgrade recommendation from the team at JP Morgan earlier this year. The broker recommended the share price as a 'sell' and reduced the price target from $3.30 to $3.

The company also faced calls to pass more COVID savings back to members from the Private Hospital Association chief executive Michael Ross.

The Medibank share price fell 14% between market close on 7 January and 31 January alone. Elective surgery bans in Victoria and NSW amid the Omicron variant wave could have impacted the company's shares.

On 25 February, the Medibank share price slipped 4% on the back of the company's H1 FY22 results. Net profit after tax (NPAT) dropped 2.7% to $220.2 million. The company reported elective surgery restrictions during the COVID-19 pandemic had taken a toll.

Commenting on the elective surgery bans, CEO David Koczkar said:

We've always committed to return all permanent net claims savings due to COVID. And while we are pleased to be able to support our customers throughout the pandemic, now is the right time for governments to minimise future use of restrictions to elective surgery.

In late February, Medibank appointed Kathryn Fagg AO and Peter Everingham to the board as non-executive directors. Commenting on the appointment, chairman Mike Wilkins said:

As our company continues to grow, and as we continue to increase our focus on delivering for our customers, we are pleased to be able to appoint two new directors with such extensive experience and a proven track record.

These new non-executive directors will commence their roles on 31 March.

In better news for the company, Broker Credit Suisse has recently put a $3.50 price target on the Medibank share. This is nearly 15% more than the current share price.

Medibank declared a franked interim dividend of 6.1 cents per share

Medibank share price snapshot

The Medibank share price has climbed nearly 5% in the past 12 months, but it has shed 6% in the past month.

For perspective, the benchmark S&P/ASX 200 Index (ASX: XJO) has leapt 9% in the past 52 weeks.

Medibank has a market capitalisation of about $8.4 billion based on its current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 1,173% in a year, what do 4DMedical shares have over other healthcare stocks?

Expert explains why 4DMedical is somewhat sheltered from today's sector headwinds.

Read more »

A couple sits on the bed in their hotel room wearing white robes, both have seen the bad news on their phones.
Earnings Results

What's going on with ResMed shares today?

The sleep disorder treatment company has released its third-quarter update this morning.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Healthcare Shares

Resmed reports double-digit revenue and profit increases in Q3 FY26

Resmed posted double-digit revenue and profit growth in Q3 FY26, with management confident about continued momentum.

Read more »

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares crashed in April, but is a comeback looming?

This ASX 200 healthcare stock is caught between short-term pain and long-term potential.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.
Healthcare Shares

What's making healthcare the worst sector on the ASX 200, down 39% in a year?

An expert outlines the key headwinds weighing on the industry and share prices today.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Good news, falling shares: What's dragging this ASX stock lower?

In biotech, strong updates don't always push the share price higher.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Healthcare Shares

Guess which ASX All Ords healthcare share is rocketing 18% in Thursday's sinking market

Investors are piling into the ASX healthcare share on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

Mesoblast shares: Cash burn falls and Ryoncil® sales climb

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter.

Read more »